Status:
NOT_YET_RECRUITING
Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)
Lead Sponsor:
Neuromed IRCCS
Conditions:
Huntington Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
Huntington's disease (HD) is a neurodegenerative pathology characterized by choreic hyperkinesias which represent the typical motor symptom and are represented by involuntary, aimless, irregular, recu...
Detailed Description
A two-week course of repetitive magnetic stimulation (rTMS) has been shown to exert persistent clinical beneficial effects, reducing peak drug dyskinesias for up to four weeks after the end of the sti...
Eligibility Criteria
Inclusion
- Diagnosis of HD genetically confirmed (number of CAG triplets ≥36)
- Presence of chorea movements quantified with a score ≥ 10 on the sum of the scores of the subscale of the Unified Huntington's Disease Rating Scale (UHDRS) for the evaluation of maximum chorea for the facial, oro-bucco-lingual, truncal, four limbs districts
- Ability to provide written informed consent
- No changes in drug therapy in the 8 weeks prior to the baseline visit
- No changes in drug therapy for the entire duration of the study
Exclusion
- Contraindications to exposure to magnetic fields
- Patients who are pregnant or breastfeeding
- Presence of significant risk of suicidal behavior
- Patients who have received an investigational drug in a clinical trial within 30 days of the baseline visit or have planned to use such an investigational drug during the study
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06976983
Start Date
September 1 2025
End Date
April 30 2026
Last Update
May 16 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.